Comorbidities and challenges affecting African Americans with HIV infection.

作者: M. Keith Rawlings , Henry L. Masters

DOI: 10.1016/S0027-9684(15)31550-9

关键词:

摘要: The significant disparities in health outcomes that exist among racial minorities the United States are clearly evident HIV epidemic. disproportionately affects minorities, African Americans particular. Current treatment of HIV/AIDS is complicated by medical problems such as hepatitis, diabetes and dyslipidemia, which also affect can significantly impact complexity clinical care. In addition, untreated psychological depression societal barriers to adequate care may decrease adherence increase HIV-related morbidity mortality Americans. Consideration these issues healthcare providers necessary optimize improve for with infection.

参考文章(38)
John G Gerber, Susan L Rosenkranz, Carl J Fichtenbaum, Jose M Vega, Amy Yang, Beverly L Alston, Susan W Brobst, Yoninah Segal, Judith A Aberg, Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. Journal of Acquired Immune Deficiency Syndromes. ,vol. 39, pp. 307- 312 ,(2005) , 10.1097/01.QAI.0000167156.44980.33
Ronald A. Brooks, Mark A. Etzel, Ernesto Hinojos, Charles L. Henry, Mario Perez, Preventing HIV Among Latino and African American Gay and Bisexual Men in a Context of HIV-Related Stigma, Discrimination, and Homophobia: Perspectives of Providers Aids Patient Care and Stds. ,vol. 19, pp. 737- 744 ,(2005) , 10.1089/APC.2005.19.737
Roy M Gulick, Heather J Ribaudo, Cecilia M Shikuma, Christina Lalama, Bruce R Schackman, William A Meyer, Edward P Acosta, Jeffrey Schouten, Kathleen E Squires, Christopher D Pilcher, Robert L Murphy, Susan L Koletar, Margrit Carlson, Richard C Reichman, Barbara Bastow, Karin L Klingman, Daniel R Kuritzkes, AIDS Clinical Trials Group, A5095 Study Team, Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. ,vol. 296, pp. 769- 781 ,(2006) , 10.1001/JAMA.296.7.769
Carl J. Fichtenbaum, John G. Gerber, Susan L. Rosenkranz, Yoninah Segal, Judith A. Aberg, Terrence Blaschke, Beverly Alston, Fang Fang, Bradley Kosel, Francesca Aweeka, Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 AIDS. ,vol. 16, pp. 569- 577 ,(2002) , 10.1097/00002030-200203080-00008
David Burger, Ilse van der Heiden, Charles la Porte, Marchina van der Ende, Paul Groeneveld, Clemens Richter, Peter Koopmans, Frank Kroon, Herman Sprenger, Jan Lindemans, Paul Schenk, Ron van Schaik, Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: The effect of gender, race, and CYP2B6 polymorphism British Journal of Clinical Pharmacology. ,vol. 61, pp. 148- 154 ,(2006) , 10.1111/J.1365-2125.2005.02536.X
Kenneth Wells, Ruth Klap, Alan Koike, Cathy Sherbourne, Ethnic Disparities in Unmet Need for Alcoholism, Drug Abuse, and Mental Health Care American Journal of Psychiatry. ,vol. 158, pp. 2027- 2032 ,(2001) , 10.1176/APPI.AJP.158.12.2027
H. J. Ribaudo, D. W. Haas, C. Tierney, R. B. Kim, G. R. Wilkinson, R. M. Gulick, D. B. Clifford, C. Marzolini, C. V. Fletcher, K. T. Tashima, D. R. Kuritzkes, E. P. Acosta, Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study Clinical Infectious Diseases. ,vol. 42, pp. 401- 407 ,(2006) , 10.1086/499364
M GLESBY, J ABERG, M KENDALL, C FICHTENBAUM, R HAFNER, S HALL, N GROSSKOPF, A ZOLOPA, J GERBER, Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clinical Pharmacology & Therapeutics. ,vol. 78, pp. 143- 153 ,(2005) , 10.1016/J.CLPT.2005.04.005